Deborah Palestrant, Ph.D.Partner, Head of 4:59 at 5AM Ventures
Deborah Palestrant, Ph.D., M.B.A joined 5AM Ventures in 2018 as Partner, Head of 4:59. Previously, Dr. Palestrant was Vice President of Corporate Development & Strategy at Relay Therapeutics, where she executed business strategy including alliances, partnerships, and other collaborations and led communications. She has over 15 years of life sciences industry experience including drug discovery, company creation, operations, business development, and strategy. Following her postdoctoral fellowship, Deborah was a lab head at the Novartis Institutes for Biomedical Research, where she advanced multiple structure-based drug discovery programs. In 2010, Deborah joined Third Rock Ventures as a senior associate and helped to build and launch Blueprint Medicines (NASDAQ: BPMC). Upon its launch, Deborah served an interim role in operations at Blueprint Medicines. Subsequent to her return to Third Rock Ventures, Deborah helped to conceive and launch Editas Medicine (NASDAQ: EDIT), and as part of the original founding team, she led the business development group until joining Relay Therapeutics.
Deborah holds a Ph.D. in biochemistry and molecular biophysics from Columbia University, an M.B.A from Northeastern University, and was Damon Runyon Cancer Research Foundation Postdoctoral Fellow at The Scripps Research Institute.